Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Operating Income: ¥399 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688796 Biocytogen Pharmaceuticals (Beijing) Co Ltd SHSE:688796
53 GF Score
Price ¥134.13
GF Value ¥76.48
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co Operating Income?

Biocytogen Pharmaceuticals (Beijing) Co SHSE:688796 -2.80% 53 Operating Income is ¥399 Mil as of Jun. 2026. GuruFocus rates SHSE:688796 with a GF Score™ of 53/100 and a GF Value™ of ¥76.48 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Biocytogen Pharmaceuticals (Beijing) Co's Operating Income for the six months ended in Jun. 2026 was ¥270 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was ¥399 Mil.

Warning Sign:

Biocytogen Pharmaceuticals (Beijing) Co Ltd has recorded a loss in operating income at least once over the past 3 years.

Operating Margin % is calculated as Operating Income divided by its Revenue. Biocytogen Pharmaceuticals (Beijing) Co's Operating Income for the six months ended in Jun. 2026 was ¥270 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Revenue for the six months ended in Jun. 2026 was ¥941 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % for the quarter that ended in Jun. 2026 was 28.67%.

Biocytogen Pharmaceuticals (Beijing) Co's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biocytogen Pharmaceuticals (Beijing) Co's annualized ROC % for the quarter that ended in Jun. 2026 was 21.31%. Biocytogen Pharmaceuticals (Beijing) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 33.83%.

Biocytogen Pharmaceuticals (Beijing) Co  (SHSE:688796) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biocytogen Pharmaceuticals (Beijing) Co's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=539.886 * ( 1 - 2.778% )/( (2426.46 + 2500.813)/ 2 )
=524.88796692/2463.6365
=21.31 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3724.364 - 123.279 - ( 1585.149 - max(0, 930.306 - 2104.931+1585.149))
=2426.46

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3642.552 - 102.869 - ( 1038.87 - max(0, 498.651 - 1645.215+1038.87))
=2500.813

Note: The Operating Income data used here is two times the semi-annual (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Biocytogen Pharmaceuticals (Beijing) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=610.166/( ( (1365.842 + max(151.031, 0)) + (1750.228 + max(340.235, 0)) )/ 2 )
=610.166/( ( 1516.873 + 2090.463 )/ 2 )
=610.166/1803.668
=33.83 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(300.31 + 174.75 + 44.722) - (123.279 + 103.759 + 141.713)
=151.031

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(313.195 + 219.205 + 73.945) - (102.869 + 116.942 + 46.299)
=340.235

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=269.943/941.389
=28.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Biocytogen Pharmaceuticals (Beijing) Co Operating Income Related Terms

Biocytogen Pharmaceuticals (Beijing) Co Operating Income Historical Data

* Premium members only.

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co Operating Income Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
Get a 7-Day Free Trial -541.20 -621.08 -317.42 126.24 207.09

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Apr20 Dec21 Dec22 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Operating Income Get a 7-Day Free Trial Premium Member Only -1.28 127.52 78.09 128.99 269.94
SHSE:688796
53GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd SHSE:688796
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocytogen Pharmaceuticals (Beijing) Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ¥399 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of ¥399 Mil mean?
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) has a Operating Income of ¥399 Mil as of Jun. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors.
Is Biocytogen Pharmaceuticals (Beijing) Co's Operating Income too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Operating Income is ¥399 Mil. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Operating Income compare to VRTX and REGN?
Biocytogen Pharmaceuticals (Beijing) Co's Operating Income of ¥399 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Biotechnology company?
A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. Biocytogen Pharmaceuticals (Beijing) Co's current Operating Income is ¥399 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥76.48, compared to a current price of ¥134.13 — trading 75.4% above its estimated fair value. The current Operating Income is ¥399 Mil. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796), the current Operating Income is ¥399 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of ¥134.13 is trading 75.4% above its estimated GF Value™ of ¥76.48. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.

Key valuation signals for SHSE:688796:

  • Operating Income: ¥399 Mil
  • GF Value™: ¥76.48 vs. price of ¥134.13 (75.4% above fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the SHSE:688796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong KongI54:Germany
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
53GF Score

Get the complete analysis for SHSE:688796

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥134.13
Price
¥76.48
GF Value